Analyst James Orsborne from Stifel Nicolaus maintained a Buy rating on Open Orphan Plc (HVO – Research Report) and decreased the price target to p30.00 from p35.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
James Orsborne’s rating is based on a combination of factors that highlight Open Orphan Plc’s growth potential and strategic positioning. The company recently secured a £2 million contract for hVIVO’s human metapneumovirus (hMPV) disease model, indicating strong momentum in acquiring new business. This contract, although initially small, suggests potential for more significant future projects once the model is fully validated and receives regulatory approval.
Furthermore, the global focus on hMPV due to recent outbreaks and the lack of specific treatments or vaccines enhances the market opportunity for hVIVO. The company’s successful pilot trials have demonstrated a safe and effective model, which could lead to expanded client offerings. Additionally, Orsborne anticipates revenue growth, supported by hVIVO’s core business and new contracts, while the current share price presents an attractive entry point for investors, with expectations of increasing earnings and margins in the coming years.